Pipeline notes:
Pipeline as of September 2020
Entire pipeline not shown
C2 is only one of Minerva’s panel of antibodies that target MUC1*
huMNC2-CAR44 is currently in Phase I/II for MUC1* positive breast cancers
Minerva is currently seeking partners to accelerate trials with this CAR in other cancers
1XX technology was licensed from Memorial Sloan Kettering Cancer Center
Minerva is currently seeking partners interested in developing ADC or bispecific approaches
Minerva’s regenerative medicine platform is available for licensing for any cell type